• Selexis, Teneobio Enter Second Services Agreement contractpharma
    December 21, 2018
    Selexis SA and Teneobio, Inc. have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology Platform
  • Alvotech, Fuji Pharma Expand Biosimilars Alliance contractpharma
    December 19, 2018
    Alvotech and Fuji Pharma have entered an exclusive agreement for the development and commercialization of biosimilars in Japan. Fuji is acquiring a 4.2% stake in Alvotech for approximately $50 million
PharmaSources Customer Service